Tivic Health Systems, Inc. - TIVC STOCK NEWS

Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, has announced its 2024 Virtual Annual General Meeting of Shareholders. The meeting is scheduled for Friday, August 9, 2024, at 10:00 a.m. Pacific Time. Stockholders of record as of June 17, 2024, are eligible to attend and vote. The virtual format aims to provide a consistent and convenient experience for all stockholders.

To participate, stockholders will need to use the control number provided on their Notice or proxy card. Beneficial owners without a control number can access the meeting through their brokerage firm's website. The company's Proxy Statement and Annual Report on Form 10-K for 2023 are available on Tivic Health's investor relations website.

Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, has expanded its intellectual property portfolio with three new patents granted in the US and Europe. The patents protect:

1. Adaptive trigger technology for microcurrent stimulation devices
2. Methods to identify preferred treatment points
3. Dynamic adjustment of stimulation voltage during treatment

These innovations enhance device performance, comfort, and user experience. Blake Gurfein, Chief Scientific Officer, emphasized the company's commitment to building a robust IP portfolio for current and future products, including non-invasive vagus nerve stimulation assets.

Tivic Health has appointed Christina Valauri to its board of directors, effective July 1, 2024. Valauri, who has been a strategic advisor to the company since April 2023, brings over 30 years of capital markets experience. She has held leadership roles at Cantor Fitzgerald, Credit Lyonnais, ING, and Natixis, and has extensive experience in healthcare equity research. Valauri is expected to enhance Tivic Health's growth and governance, particularly in bioelectronic medicine. Additionally, Karen Drexler resigned from the board effective September 30, but will continue as a strategic advisor.

Tivic Health Systems (Nasdaq: TIVC) announced the initiation of the second phase of its clinical work to advance its non-invasive cervical vagus nerve stimulation (ncVNS). This phase involves a collaboration with The Feinstein Institutes for Medical Research at Northwell Health to optimize the ncVNS device for specific clinical indications. A 20-person clinical trial will be conducted, focusing on refining electrode positioning and key electrical waveform parameters. The first phase demonstrated significant changes in biomarkers for the brain, heart, and autonomic nervous system. This next phase aims to tailor the therapy to specific clinical indications and accelerate product development. VNS is a growing market within the $8.3 billion neurostimulation sector, with a projected CAGR of 12.2% from 2023 to 2032.

Tivic Health announced its Q1 2024 financial results and subsequent events, marking significant progress in the bioelectronics field. The company reported a gross profit increase of 48% and a reduction in operating loss by nearly 30% year-over-year. Net loss decreased to $1.5 million from $2.1 million in Q1 2023. Despite an 11% drop in revenue to $334 thousand, gross margin improved to 50% from 30%.

Significant milestones included the completion of patient enrollment in a vagus nerve stimulation study and the launch of ClearUP 2.0. A recent public offering raised $4 million, boosting cash reserves to $4.7 million as of May 14, 2024.

Key developments also included a major distribution agreement and positive clinical trial results demonstrating the efficacy of their non-invasive vagus nerve stimulation technology. The company continues to invest in its intellectual property portfolio.

Tivic Health, trading under the ticker TIVC, will announce its Q1 2024 financial results on May 15th via a pre-recorded conference call and webcast. The call is scheduled for 1:30 PM PT / 4:30 PM ET. The company specializes in developing and commercializing bioelectronic medicine. Stakeholders can join the call using the provided toll-free and international numbers, or view the webcast online.

Tivic Health Systems announced the closing of a $4.0 million public offering. The offering included 4,710,000 shares of common stock, Series A warrants for 4,710,000 shares, and Series B warrants for 7,065,000 shares, all priced at $0.85 per share. The Series A warrants are exercisable immediately and expire in one year, while the Series B warrants also exercisable immediately, expire in five years. Maxim Group served as the sole placement agent. The gross proceeds before fees and expenses amounted to $4.0 million. The offering was made through a registration statement declared effective by the SEC on May 9, 2024. Investors can access the final prospectus on the SEC website.

Tivic Health Systems, a health tech company, announced the pricing of a public offering consisting of common stock and warrants, expecting to raise approximately $4.0 million. The offering includes Series A and Series B warrants with different terms and exercise prices. The closing is scheduled for May 13, 2024, subject to customary conditions. Maxim Group is the sole placement agent for the offering.

Tivic Health announced successful completion of a pilot research study showing the effectiveness of their non-invasive vagus nerve stimulation approach in inducing responses in the autonomic, cardiac, and central nervous systems. Results included a 97% increase in heart rate variability and changes in brain activity consistent with reduced arousal and anxiety. The company aims to improve bioelectronic medicine and expand into new market segments. VNS is a growing market with significant potential in various medical conditions.